What is GenScript?
Founded in 2002 and headquartered in Piscataway, New Jersey, GenScript operates as a premier provider of life science services and products. The organization maintains a sophisticated multi-platform business model that encompasses four primary pillars: a comprehensive life-science services and products platform, a biologics contract development and manufacturing organization (CDMO), an industrial synthetic products division, and an integrated global cell therapy platform. By offering one-stop solutions to the global research community, GenScript has established itself as an essential partner for academic institutions, pharmaceutical companies, and industrial biotech firms seeking to accelerate their development pipelines.
The company's market authority is derived from its ability to integrate complex synthetic biology workflows with large-scale manufacturing capabilities. This operational synergy allows GenScript to maintain a competitive edge in the rapidly evolving biotech landscape, ensuring that it remains at the forefront of therapeutic discovery and industrial application.
How much funding has GenScript raised?
GenScript has raised a total of $67.6M across 1 funding round:
Stock Offering
$67.6M
Stock Issuance/Offering (2015): $67.6M, investors not publicly disclosed
Key Investors in GenScript
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
What's next for GenScript?
Looking ahead, GenScript is positioned to capitalize on the increasing demand for outsourced biologics development and cell therapy innovation. The recent infusion of capital is expected to bolster the company's CDMO capabilities, allowing for expanded capacity in clinical-grade manufacturing and process development. As the biotech industry shifts toward more personalized medicine and complex synthetic biology, GenScript's strategic focus will likely remain on scaling its integrated platforms to meet the rigorous requirements of global regulatory standards. By maintaining its commitment to high-throughput research services and industrial-scale production, the firm is well-equipped to navigate the complexities of the modern life sciences market, driving long-term value for stakeholders and advancing the frontiers of biotechnology.
See full GenScript company page
